23-105 Review and Validation

EXECUTIVE SUMMARY

We have completed our assurance engagement of Review and Validation. This engagement was performed at the request of the UTHealth Houston (UTHealth) Audit Committee and was conducted in accordance with the International Standards for the Professional Practice of Internal Auditing.

Background
UTS 142.1, Section 7 Internal Audit Risk Assessment and Certification of the Monitoring Plan, last amended or reviewed on June 25, 2019, states, “The institutional Chief Audit Executive shall perform an annual risk assessment of the Monitoring Plan. The institutional Chief Audit Executive will certify within 60 days of the fiscal year end, to the Financial Reporting Officer of U. T. System Administration, whether an audit was performed based on the risk assessment and discussion with the institutional audit committee.”

Objectives
Our objective was to determine whether UTHealth complies with UTS Policy 142.1 on Review and Validation. Specifically, we wanted to determine if:

- UTHealth followed its monitoring plan for segregation of duties and reconciliation of accounts
- Account owners submitted sub certifications timely
- Assertions of segregation of duties and account reconciliations are valid

Scope
The scope period was fiscal year 2022.

Conclusion
Overall, we determined UTHealth is in compliance with its monitoring plan for segregation of duties, reconciliation of accounts, and timely submission of sub certification letters. In addition, we obtained reasonable assurance assertions of segregation of duties and reconciliations of accounts were valid.

In our opinion, UTHealth complies with UTS Policy 142.1 on Review and Validation.

We would like to thank the Finance & Business Services staff and management who assisted us during the engagement.

Daniel G. Sherman, MBA, CPA, CIA
Vice President & Chief Audit Officer
OBSERVATION RATINGS

<table>
<thead>
<tr>
<th>Priority</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority</td>
<td>An issue that, if not addressed timely, has a high probability to directly impact achievement of a strategic or important operational objective of UTHealth or the UT System as a whole.</td>
</tr>
<tr>
<td>High</td>
<td>An issue considered to have a medium to high probability of adverse effects to a significant office or business process or to UTHealth as a whole.</td>
</tr>
<tr>
<td>Medium</td>
<td>An issue considered to have a low to medium probability of adverse effects to an office or business process or to UTHealth as a whole.</td>
</tr>
<tr>
<td>Low</td>
<td>An issue considered to have minimal probability of adverse effects to an office or business process or to UTHealth as a whole.</td>
</tr>
</tbody>
</table>

NUMBER OF PRIORITY OBSERVATIONS REPORTED TO UT SYSTEM
None.

MAPPING TO A&AS FY 2023 RISK ASSESSMENT

<table>
<thead>
<tr>
<th>Reference</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIN 113</td>
<td>Processes to ensure compliance with the requirements of UTS 142.1 have not been established.</td>
</tr>
</tbody>
</table>

DATA ANALYTICS UTILIZED
None.

ENGAGEMENT TEAM

VP/CAO – Daniel G. Sherman, MBA, CPA, CIA
Supervisor – Kathy Tran, CIA, CISA, CFE, CGAP
Staff – Casandra Wiley

END OF FIELDWORK DATE
October 24, 2022

ISSUE DATE
October 25, 2022

REPORT DISTRIBUTION

Audit Committee
Kevin Dillon
Ana Touchstone
Michael Tramonte
Scott Barnett